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Abstract
Large-scale whole genome sequence datasets offer novel opportunities to identify genetic variation 
underlying human traits. Here we apply genotype imputation based on whole genome sequence 
data from the UK10K and the 1000 Genomes Projects into 35,981 study participants of European 
ancestry, followed by association analysis with twenty quantitative cardiometabolic and 
hematologic traits. We describe 17 novel associations, including six rare (minor allele frequency 
[MAF]<1%) or low frequency variants (1%<MAF<5%) with platelet count (PLT), red cell indices 
(MCH, MCV) and high-density lipoprotein (HDL) cholesterol. Applying fine-mapping analysis to 
233 known and novel loci associated with the twenty traits, we resolve associations of 59 loci to 
credible sets of 20 or less variants, and describe trait enrichments within regions of predicted 
regulatory function. These findings augment understanding of the allelic architecture of risk 
factors for cardiometabolic and hematologic diseases, and provide additional functional insights 
with the identification of potentially novel biological targets.
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Introduction
Heritable influences to cardiometabolic and hematologic traits have been identified across 
the allele frequency spectrum. Rare (defined here as minor allele frequency [MAF] < 1%) 
and highly penetrant variants with large phenotypic effects have been identified, but account 
for a small proportion of phenotypic variance 1,2. At the other end of the allelic frequency 
spectrum, genome and exome wide association analyses based on sparse arrays have 
identified thousands of common (MAF ≥ 5%) and low frequency (MAF 1-5%), single 
nucleotide variants (SNVs), with modest effects 3–11. To investigate the influence of rare, 
less-frequent, and common variation on complex traits, we applied whole genome 
sequencing (WGS) in individuals from two British cohorts, the St Thomas’ Twin Registry 
(TwinsUK)12 and the Avon Longitudinal Study of Parents and Children (ALSPAC) 13 as 
part of the UK10K project. Sequencing was performed at an average depth of 7x across 
3,781 individuals. The final dataset is described in 14 and consists of 42 million single 
nucleotide variants (SNVs), 3.5 million insertion/deletion polymorphisms (INDELs) and 
nearly 18,000 large deletions.
The initial phase of the UK10K Project applied a variety of statistical tests to identify rare 
alleles associated with a broad range of complex phenotypes. Besides yielding the first 
examples of novel trait associations identified through population-based WGS 15,16, the 
project provided a large-scale empirical evaluation of strategies for testing associations in 
the low and rare allele frequency range. First, the study demonstrated an overall paucity of 
low-frequency alleles with high-penetrance in the space where it was powered (defined by 
each variant’s effect >1.2 standard deviations and MAF ~0.5%), suggesting that in this 
frequency range novel discoveries required larger samples with greater statistical power. 
Further, it defined through simulations and empirical evidence the allelic space where 
genotype imputation was expected to be most beneficial for association studies. Finally, it 
developed a new genotype imputation panel based on WGS that significantly enhances 
imputation accuracy for low-frequency and rare variants in populations of European descent 
17, substantially improving resolution and power in this frequency range.
Capitalising on these tools and discoveries, we sought to increase the representation of rare 
variation in association studies of cardiometabolic and hematologic traits through imputation 
using the UK10K and 1000 Genomes haplotype reference panels, studying up to 35,981 
individuals of European descent from 18 different studies. After testing for association 
between 17 million sequence variants and 20 quantitative traits, we report on 17 novel 
variants associated with seven different traits. We applied fine-mapping approaches that 
exploit these more comprehensive imputation reference panels to identify sets of variants 
with high (>95%) joint probability of being causal at 59 different loci. By expanding the 
number of discovered loci for seven cardiometabolic traits and narrowing down known 
association signals to small sets of variants, our results demonstrate the utility of large 
imputation reference panels for the discovery and refinement of associations with complex 
quantitative traits.
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Results
Common, low frequency and rare variant associations
We considered 20 different quantitative traits representing five biomedical trait groups: 
serum lipids (HDL, LDL, TC, TG), inflammatory biomarkers (CRP, IL6), renal function 
(uric acid, creatinine), fasting glycemic traits (glucose, insulin, HOMA-B, HOMA-IR) and 
haematological indices (HGB, RBC, MCH, MCHC, MCV, PCV, PLT, WBC) (Figure 1; see 
Figure legend for trait abbreviations). In the discovery stage, we tested associations of up to 
15,188,514 autosomal and 468,312 X-linked SNVs and 1,311,244 biallelic indels 
(MAF≥0.1%) in up to 3,210 study participants with shallow WGS data available (depending 
on trait), and combined them with up to 32,904 participants from independent population 
based samples with SNPs imputed to the UK10K panel, or a combination of WGS reference 
panels 17,18 (Supplementary Note and Supplementary Table 1). We tested associations 
within each study using linear regression (Online Methods, Supplementary Table 1, 
Supplementary Table 2 and Supplementary Figure 1), and combined summary statistics from 
different studies with inverse-variance weighted meta-analyses.
This effort yielded 171 independent associations (p-value ≤5x10-8) in the discovery meta-
analysis, of which 110 represent previously reported GWAS signals, 48 mapped to 
statistically independent variants at known GWAS signals (secondary signals) and 13 to 
putative new associations. We obtained replication for 58/61 variants in as many as 102,505 
independent samples from 5 different studies. We detected a total of 17 novel associations 
that were robustly replicated (defined as a replication p-value < 0.05/58 and meta-analysis p-
value <8.31x10-9) in independent samples (Table 1 and Supplementary Table 3). Of these, 
ten were novel loci, or regions of the genome not previously associated with the trait of 
interest. Additionally, we identified seven variants defined as secondary signals, where the 
genetic variant mapped to within 1Mb of a locus already associated with the trait, but was 
statistically independent of any previously reported association (Online Methods). Of the 17 
variants reported, three were coding and the rest were located in non-coding putative 
regulatory regions (see Box 1).
The ten novel associations all involved hematologic traits and included seven variants 
associated with platelet count (PLT), two variants associated with white blood cell count 
(WBC), and one variant associated with haematocrit (PCV). Two of the ten loci were 
previously associated with other traits. The rs1801689 missense variant (p.Cys325Gly) in 
APOH associated with higher PLT was previously associated with higher low-density 
lipoprotein (LDL) cholesterol 19. SHROOM3 rs10008637 associated with higher PCV is an 
LD proxy (r2=0.98) for rs13146355, a common intronic variant associated with lower serum 
creatinine in East Asians 20 and higher serum magnesium in Europeans 21. One of the PLT-
associated loci, synonymous variant rs150813342 of GFI1B, is reported concurrently in an 
independent exome sequencing data set 22.
Among the seven secondary signals within 1Mb of a known locus, one was associated with 
HDL (an intronic variant of ABCA1), one with uric acid (an intronic variant of SLC2A9) 
and five with hematological indices (PLT, WBC, MCV and MCH). Four loci harboured both 
common and independent, lower frequency variants (CCDN3 and MCV; THPO and PLT; 
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GCSAML and PLT; ABCA1 and HDL). The low-frequency ABCA1 intronic variant 
rs3824477 (MAF=0.02) was in strong LD (r2=0.94) with an ABCA1 missense variant 
(rs2066718 = p.Val771Leu) nominally associated with HDL (p-value=10-4) in a targeted 
lipid gene re-sequencing study 23.
Three out of the ten novel loci, and three out of the seven secondary signal associations were 
observed for low frequency (MAF 1-5%) or rare (MAF <1%) variants, extending our 
understanding of the genetic architecture of cardiometabolic traits. To illustrate, we 
considered the effect sizes and allele frequencies of both known and novel variants for HDL 
and PLT (Figure 2a). Although we identified one rare variant with a large effect size 
(rs150813342 in GFI1B), the effect sizes of the other novel low-frequency variants were 
similar to those that have been previously reported in GWAS of common variants. Indeed, 
for variants with MAF ≥0.5%, we had 80% power to detect associations with effect sizes of 
0.25, 0.25, 0.35 and 0.55 trait standard deviations for HGB, LDL, HOMA-B and IL6, 
respectively (Figure 2b). Although there may be rare variants of large effect that we were 
unable to identify in the current study, we likely did not miss large effect variants with MAF 
≥0.5% and sufficient sequencing quality in European populations.
Functional enrichment analysis of trait associated variants
The majority of the associations we identified are found in non-coding regions, where the 
underlying cellular or molecular mechanisms are poorly defined. To evaluate the functional 
and regulatory properties of this set of variants, we estimated the extent to which 
associations for each of the 20 traits were non-randomly distributed across various coding, 
non-coding regulatory, and cell type-specific elements across the genome. We retrieved 
experimentally derived annotations from 1,005 genome-wide datasets from the GENCODE, 
ENCODE and Roadmap projects (Supplementary Table 4). We then used a novel 
nonparametric approach (GARFIELD) (Supplementary Note) to derive fold enrichment (FE) 
statistics for trait associated SNPs within each annotation, where SNPs were selected from 
genome-wide datasets based on their strength of association with each trait (Online 
Methods). An example of the results for one trait (PLT) and one annotation type (DHS 
hotspots) is shown in Figure 3, with all results summarised in Supplementary Table 5 and 
Supplementary Figure 2.
Lipid and hematological traits displayed ubiquitous and marked enrichment patterns, with 
151 (p<10-8) and 906 (p<10-5) overall significant FE statistics for serum lipids, and 237 
(p<10-8) and 749 (p<10-5) for hematological traits, respectively. As the most extreme cases, 
we found that associations with RBC were enriched in enhancers of the erythroid cell line 
K562 (FE=39.63, empirical p-value=2x10-5), while associations with WBC were enriched in 
footprints of CD20+ cells (FE=22.16, empirical p-value<10-5). The most significant 
association for LDL was within TSS chromatin states measured in the liver HepG2 cell line 
(FE=19.53, empirical p-value<10-5). Conversely, inflammatory and renal traits displayed 
weak patterns of enrichment. There was a significant enrichment of associations (FE=4.44-
fold, empirical p-value=10-5) with creatinine within DHS hotspots of fetal kidney. Uric acid 
associations were weakly enriched in a small number of liver and fetal intestine annotations. 
Unexpectedly, we observed enrichment of triglycerides (TG) in HMVEC-LLy (lymphatic 
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microvascular endothelial cells) footprints for SNPs with p<10-5 (FE=9.75, empirical p-
value<10-5), which is much larger than that observed for the broader DHS hotspots 
(FE=4.30, empirical p-value<10-5). By contrast, there was no significant enrichment for 
footprints of the expected most relevant HepG2 (a well established hepatocyte cellular 
model for cholesterol metabolism) cell type.
Fine mapping of loci using dense imputation from WGS
Linkage disequilibrium and incomplete ascertainment of variants in a given region of 
interest present significant challenges for pinpointing the causal variant[s] driving an 
association. To fine-map the causal variant[s] at associated loci, we exploited the high 
density of our whole-genome sequence reference panels to define the posterior probability of 
each variant being causal given all other variants in the region. We selected 417 regions with 
informative associations (p-value≤10-5, Online Methods) in the initial discovery meta-
analysis and applied three distinct Bayesian approaches (namely ‘Maller’ 24, ‘FINEMAP’ 
25 and ‘CAVIARBF’ 26) (Online Methods). For each of the three methods, we created 95% 
credible sets by ranking variants based on their decreasing posterior probability (PP) of 
association. These credible sets contain the minimum list of variants that jointly have at least 
95% probability of containing the causal variant. We focused on 59 known or novel loci 
where the three methods identified a credible set of less than 20 variants, and where all 
variants were either directly genotyped or well imputed (Figure 4, Supplementary Table 6 
and Supplementary Figure 3).
Overall, 95% credible sets contained an average of 6.9 (standard deviation = 5.9) variants 
per locus when considering the union of all methods, or 5.5 (standard deviation = 4.7) when 
considering the intersection. In 45 cases the three methods yielded identical 95% credible 
sets, including 13 known and 5 novel loci where a single variant was predicted to be 
causative with posterior probability ~1 by all three methods. Of these 18 loci, five involved 
well-characterised missense variants (rs11591147 at PCSK9, rs1260326 at GCKR, rs855791 
at TMPRSS6, rs7412 at APOE and rs429358 as a secondary signal at APOE). Missense 
variants were included in the 95% credible sets at several other loci (ABCG2, APOB, 
CD300LG, CILP2, HFE, PSORCS1, SH2B3, SLC30A8 and APOH). At four loci the 
credible interval included a variant predicted to alter an essential splicing donor/acceptor 
motif (GCSAML, MLXIPL, BET1L and CETP), and at the other three (DNAH11, IKZF1 
and GFI1B) the 95% credible set included synonymous sites. For all other loci, the causative 
set included UTR, intergenic and intronic sites.
For each known locus we compared the variants in the fine-mapped set with published 
evidence from functional validation studies (Supplementary Table 6). Of the 59 discrete 
genomic regions, 40 were associated with one trait and 19 were associated with multiple 
traits. Further, 25 (42%) were known to have at least one causative variant previously 
experimentally or functionally validated. At 20 of the 25 loci, the previously validated 
functional variant was contained within the 95% credible interval identified using one or 
more fine-mapping methods. In 11 regions, the known causal variant was ranked with the 
highest posterior probability by at least one fine-mapping method. We also identified several 
other examples where the credible sets define high-priority variants for downstream follow-
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up. Among these are CRP rs1205 a 3’ UTR variant associated with C-reactive protein (CRP) 
that is located in a predicted liver enhancer region that alters a glucocorticoid receptor 
(NR3C1) transcription factor binding site; rs1822534 a regulatory region variant upstream of 
PPARG associated with PLT; ARHGEF3 rs1354034, an intronic variant associated with PLT 
located in a predicted enhancer region in hematopoietic and primary T cells (Roadmap 
epigenomics chromatin state) and predicted to alter a GATA motif; the total cholesterol 
(TC)-associated variant rs2169387 located in a predicted liver/muscle enhancer region 
several hundred kb upstream of PPP1R3B; the TC-associated ABCA1 rs2740488 variant 
located in a liver-specific promoter region; the PLT-associated variant rs12005199 located in 
a putative enhancer region upstream of AK3 bound by GATA1/2 and TAL1; PCV-associated 
HK1 intronic variant rs17476364 located in a hematopoietic cell enhancer region; and the 
TG-associated variant rs964184 located in a liver and fat enhancer within the ZNF259 3′ 
UTR.
Regulatory annotation of locus-specific findings
To inform our statistical fine-mapping approach, for every variant in a credible set we 
applied two scores for regulatory function based on cell type specific DNase I 
hypersensitivity sites (DHS): the deltaSVM score and the Contextual Analysis of 
Transcription Factor Occupancy (CATO) score (Online Methods) 27,28 (Supplementary 
Table 6). The functional activity of a variant’s effect allele is predicted by the magnitude of 
the deltaSVM score, with the sign indicating the increase or decrease of DNase I 
hypersensitivity, and therefore transcription factor (TF) binding potential, at the site. 
Similarly, the functional activity of a variant’s effect allele is predicted by the CATO score, 
where scores of 0.1 have a 51% true positive rate for perturbing known TF motifs, with the 
true positive rate increasing as the score increases to 1 28. To identify putatively causal 
variants, we considered deltaSVM scores greater than 10 in absolute value, CATO scores > 
0.1, and high PP from the statistical fine-mapping methods.
This union-of-methods approach identified several strong cases for causal variants. At the 
TRIB1 locus associated with TG, TC, and LDL traits, rs112875651 has the strongest 
supporting evidence for causality from all three fine-mapping methods (0.517, 0.532 and 
0.526) and also from extreme CATO and deltaSVM scores (0.315 and -12.31, respectively). 
Other functional variants have been suggested for the TRIB1 region, namely rs2001844 29 
(r2=0.8) and rs6982502 30 (r2=0.7), but these SNPs were four orders of magnitude less 
significant than rs112875651 in our TG analysis, suggesting that rs112875651 may be a 
causal variant at TRIB1. At the CELSR2 locus associated with LDL and TC, all three fine-
mapping methods provide evidence for causality (0.205,0.202 and 0.200) of rs12740374, 
though rs646776 (r2>0.8) is a stronger predicted causal variant from the PP estimates. 
However, additional supportive evidence for rs12740374 as the causal variant comes from a 
high CATO score (0.199) and an extreme deltaSVM score (14.37) for cell types with 
significant enrichment predicted by GARFIELD (liver and epithelial cells). The CATO and 
deltaSVM scores are also helpful when there are no obvious causal candidates from 
statistical fine-mapping. For example, at the CXCL2 locus associated with WBC, the PPs do 
not provide sufficiently strong evidence for a single causal variant. However index variant 
rs13128896 has strong functional evidence from its high CATO score (0.146) and its 
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extreme deltaSVM score (-10.71) for blood and skin cell types, with the former cell type 
being enriched for WBC associations in the GARFIELD analysis.
Integration of methods to prioritize variants for follow-up
We next combined information from fine-mapping analysis, genome-wide functional 
enrichment results and regulatory scores to assess the overall evidence supporting functional 
and causal interpretation at 66 independent regions (in 59 loci). Overall, there were 17 
regions with at least one coding variant, 33 regions with support from both functional 
enrichment and regulatory scores, 9 with functional scores only, and 6 with enrichment only 
(Figure 5a). Variants with functional enrichment overlap and those with regulatory scores 
had larger PPs of causality (average PP increase of 0.3 and 0.1, respectively) (Figure 5b), in 
contrast to variants with no such regulatory support, highlighting them as statistically more 
likely to be causal. For 24 of the 66 regions we found functional or regulatory support for 
only a fraction of the variants within credible sets (Figure 5c), ranging between 29% and 
94% of variants with annotation from at least type of evidence (mean = 74%, standard 
deviation = 18%), resulting in up to a 71% reduction in the size of the credible set. Of note, 
there was only one fine-mapped region (G6PC2 locus associated to glucose) with statistical 
support alone and no regulatory support; however the credible set contained a single causal 
variant with PP>0.999 from all three fine-mapping approaches and the variant has 
previously been shown to enhance G6PC2 pre-mRNA splicing 31.
Discussion
Our analysis demonstrates the utility of low-pass WGS data combined with SNP array data 
deeply imputed to WGS reference panels for informing studies of quantitative cardio-
metabolic and hematologic traits. By combining the UK10K and 1000 Genomes Project 
sequence data, we constructed a dense imputation reference panel that substantially 
improves upon the HapMap2 and 1000 Genomes panels. With this dense imputation 
reference panel, we investigated associations with variants as rare as 0.5% frequency.
Consistent with previous reports 17,32, our imputation accuracy declined with decreasing 
allele frequencies. Therefore, we did not consider very rare variants (MAF ≤ 0.001) or 
variants with poor imputation quality (INFO ≤ 0.4). This resulted in a substantial culling of 
the total number of variants that were identified in the UK10K project. Thus, our study may 
have missed rare-variant associations that would be identifiable in a larger study. Because 
genotype imputation provides model-based estimates of allelic probabilities in the study 
subjects, rather than hard-called empirically based genotypes, we could not reference cluster 
plots or intensity files in order to validate our findings. In this context, independent 
replication serves a critical function for validating associations from an imputation-based 
discovery effort.
Our dense imputation reference panels expanded the set of variants amenable to association 
analysis. Only one of the 17 novel loci we report was well tagged (r2 > 0.8) in HapMap2 or 
1000 Genomes Phase 1. Markers assessed in previous GWAS of PLT, haemoglobin and 
WBC poorly tagged nine of the novel loci associated with hematologic traits. However, for 
platelet count (the trait for which we observed the most and strongest associations), the 
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novel loci identified here increased the percentage of phenotypic variance explained from 
7.71% to 8.23%. Though increasingly large imputation panels are useful for investigating 
low frequency and rare-variants, considerably larger sample sizes are needed identify rare-
variants of modest-to-large effects.
For each novel locus identified we undertook epigenomic, tissue expression, and fine-
mapping analyses to describe the potential mechanism of these associations (Box 1). Our 
results implicate several genes or loci not previously known to be involved in regulation of 
blood cell counts. For example, the chromosome 22 PLT index variant rs75570992 is located 
upstream of TRABD, a gene of unknown function. Based on RNA-Seq and epigenomic data 
from BLUEPRINT, TRABD is expressed in megakaryocytes. The index variant rs75570992 
is associated with differential expression of TRABD in blood cells 33. Notably, the index 
variant is in partial LD with rs75107793 (r2=0.5), which lies upstream of the TRABD 
promoter in an H3K4me1-enriched putative megakaryocyte enhancer overlapping a ChIP-
Seq site for the hematopoietic transcription factor RUNX1.
Another newly discovered locus leading to new mechanistic insights is GFI1B rs150813342, 
a synonymous variant predicted to alter an exonic splicing enhancer. GFI1B is a 
hematopoietic transcription factor required for normal red blood cell and platelet production 
34. In a companion paper, we demonstrate that the rs150813342 variant influences the 
relative amounts of two GFI1B transcript isoforms, a full-length (long) and short isoform 
lacking the alternatively spliced exon 5 22. We further demonstrate the lineage-specific role 
of the long GFI1B isoform on megakaryocyte development. Prior studies have suggested 
that the short GFIB isoform is required for red cell production 35.
We identify several secondary, independent signals in genes previously implicated in 
regulation of blood cell counts (CCDN3, NLPR3, THPO). The new MCV-associated 
CCDN3 low-frequency variant rs112233623 was also associated with hemoglobin A2 levels 
36. rs112233623 is located within an erythroid-specific enhancer 37 and is bound by the 
hematopoietic transcription factors GATA-2 and TAL1. Similarly, NLPR3 rs117747069 is 
located in an erythroid enhancer element involved in alpha-globin gene regulation and 
overlaps GATA-2 and TAL-1 ChIP-Seq sites. A 3’ UTR variant of the thrombopoietin gene 
(THPO rs6141) was previously associated with higher PLT. We identify a second, 
independent 3’ UTR THPO signal rs78565404. By ChIPSeq, rs78565404 is bound in liver 
HepG2 cells by musculoaponeurotic fibrosarcoma oncogene homolog K (MAFK), a 
component of the hematopoietic NF-E2 transcription factor complex involved in 
megakaryopoiesis 38,39.
Several of our newly identified variants are located within genes for congenital (GFI1B, 
THPO) or acquired (APOH) platelet disorders, underscoring that more subtle genetic 
variation within genes known to contain loss-of-function variants may reflect inter-
individual differences in these complex traits. Rare loss-of-function GFI1B mutations have 
been identified in patients with congenital thrombocytopenia 40,41, while THPO mutations 
have more often been found in pedigrees with hereditary thrombocytosis. Most of the THPO 
mutations described in patients with familial thrombocytosis have involved non-coding 
sequences (splice site, 5’ UTR, intronic) gain-of-function mutations that lead to enhanced 
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THPO mRNA translation efficiency 42–45. It remains to be determined whether the two 
common 3’ UTR variants of THPO associated with higher PLT similarly enhance mRNA 
translation and thrombopoietin synthesis. Recently, the first “loss-of-function” THPO 
missense mutation (p.Arg38Cys) was associated with aplastic anemia in the homozygous 
state and mild thrombocytopenia in the heterozygous state 46.
Apolipoprotein H (ApoH) is also known as β2–glycoprotein I (β2–GPI), a major autoantigen 
for the antiphospholipid antibody syndrome (APS), a clinical disorder characterized by 
arterial and venous thrombosis 47,48. Thrombocytopenia is also sometimes a feature of the 
APS. Interestingly, the p.Cys325Gly variant encoded by APOH rs1801689 disrupts the β2–
GPI phospholipid binding site 49 ApoH/β2–GPI is also a component of LDL and binds to 
members of the LDL receptor family. The same APOH rs1801689 missense variant 
associated with higher platelet count was recently associated with higher LDL 19. β2–GPI/
antiphospholipid antibody complexes bind to LRP8, an LDL receptor present on platelets 
and endothelial cells; this interaction has been postulated to play a role in β2–GPI-mediated 
thrombosis 50,51. However, even when we controlled for LDL levels, the rs1801689 
association with platelet count remained intact, suggesting independent mechanisms driving 
the associations.
We undertook extensive fine-mapping of previously reported loci, identifying 59 loci where 
we could reduce associated signals to credible sets of 20 or less variants. We observed that 
the number of variants in the credible set was negatively correlated with the allele frequency 
of the index SNP, as expected since rare variants have fewer proxies on average. The newly 
identified loci had lower average minor allele frequencies and lower number of proxies, 
making the identification of causative variants more straightforward. Rare variants were also 
more likely to have severe consequences or lead to changes in the protein code, facilitating 
the identification of likely causative genes.
Our enrichment analyses showed that SNPs significantly associated with a phenotype of 
interest are over-represented within "functional" regions that were derived in a broad range 
of cell types and tissues. We evaluated the extent to which genetic associations for each of 
the 20 traits were enriched in different functional domains, and found that lipids and platelet 
counts were enriched in a large number of tissues and cell types compared to other traits 
displaying more localised (red cell traits) or null (renal, inflammatory traits) enrichment 
patterns. Combined with the fine-mapping experiments, we observed a positive correlation 
between the PP of causality and overlap with significantly enriched annotations. Overall this 
suggests that the process of sifting through putative causal variants can benefit from multi-
pronged approaches incorporating fine mapping analysis to additional regulatory 
information obtained from epigenomes and deltaSVM and CATO scores. This information 
in turn empowers downstream functional experiments by guiding explorations of the 
functional consequences for sets of associated variants.
By performing detailed epigenomic and functional annotation, we were able to suggest 
several novel mechanisms for variants at known loci (e.g., differential splicing for GFI1B, 
experimentally demonstrated in a companion paper) or posit strong biologic candidates for 
further functional and cellular study on platelet production (e.g., TRABD), and highlight 
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potential genetic connections between platelet count and traditional CVD risk factors such 
as cholesterol levels (APOH). Imputation using dense genotype maps affords a greater 
understanding of the relative contribution of rare and low frequency variants to complex 
traits, and allows the fine mapping of common variant association signals to manageable 
credible sets. In parallel, the development of robust functional enrichment methods and the 
overlap of fine-mapped associations with genome functional maps allowed us to pinpoint 
variants with high probability of being causal.
Online Methods
Imputation
Whole-genome sequence based haplotype reference panel—A joint reference 
panel was created as described in 17 by combining two large-scale, low read depth whole-
genome sequencing datasets, TwinsUK and ALSPAC. The UK10K final release WGS data 
of 3,781 samples and 49,826,943 sites was used. From this dataset, multi-allelic sites, sites 
containing alleles inconsistent with that of the 1000 Genomes Project (1000GP) data, and 
singletons not existing in 1000GP were removed, leaving 28,615,640 sites. SHAPEIT v2 76 
was used to re-phase the haplotypes in 3MB chunks with +/-250kb flanking regions. The 
phased chunks were then recombined with vcf-phased-join from the vcftools package 77. 
The 1000GP Phase I integrated variant set release (v3) for low-coverage whole-genomes in 
NCBI build 37 (hg19) coordinates was downloaded from 1000GP FTP site (23 Nov 2010 
data freeze). This call-set includes phased haplotypes for 1,092 individuals and 39,293,751 
variants (22 autosomes and chromosome X). For each chromosome, a summary file was 
generated and merged with that of the UK10K WGS data to identify multi-allelic sites and 
singletons not polymorphic in UK10K. These sites were excluded to create a new set of 
VCF files. The final reference panel included all 1,092 samples and 32,506,604 sites. The 
VCF-QUERY tool was used to convert the new VCF files into phased haplotypes and legend 
files for IMPUTE V2 78.
Pre-phasing and imputation of target GWAS—Genome-wide SNP data was obtained 
from each individual study, having undergone study-specific quality control (Supplementary 
Note). These samples were pre-phased using SHAPEIT v2, with the mean size of the 
windows in which conditioning haplotypes were defined set to 0.5MB. Due to the 
significantly higher number of variants in the WGS data, the re-phasing was conducted by 
3MB chunks with 250kb buffering regions. Phased genotypes were then imputed to one of 
the three WGS reference panels (UK10K alone or UK10K+1000GP or 1000GP+Genomes 
of the Netherland (GoNL)) as detailed in Supplementary Table 1. Imputation was carried out 
using IMPUTE V2 using standard settings 78.
Association Testing
Phenotype preparation—All traits were available from previous studies. Information on 
trait measurements is summarised in Supplementary Table 1. Traits were transformed by 
inverse normalization (Creatinine, Glucose, HDL, HGB, HOMA-B, HOMA-IR, CRP, IL6, 
Insulin, LDL, PCV, PLT, TC, TG and Uric Acid), square root transform (MCH), log 
transform (WBC) or left untransformed (MCHC, MCV, RBC) in order to meet the normality 
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assumption for linear model association testing. Traits were further residualised on 
associated covariables for each trait and each population sample, following detailed 
information given in the UK10K project manuscript 14 (summarised in Supplementary 
Table 4 therein). Finally, 10 principal components (PCs) were additionally regressed out 
from all traits for cohorts with unrelated individuals to further control for potential 
confounding. Information on individual study characteristics, including trait values and 
potential additional cohort-specific covariates applied are given in Supplementary Note and 
Supplementary Table 2. Histograms of trait residuals for which inverse normalization was 
not applied are shown in Supplementary Figure 4.
Study design for association testing—The study design is shown in Figure 1. Briefly, 
a total of 12,267 to 35,981 participants from 18 different studies were included in the 
discovery sample. Each cohort carried out single-marker association testing using linear 
additive models. Genotype dosages were used to account for the genotype uncertainty that 
might arise from sequencing, where each genotype was expressed on a quantitative scale 
between [0:2]. Variants that did not pass a low allele frequency threshold (MAF<0.1%), or 
imputed with low accuracy (defined by an imputation info score <0.4) were excluded from 
the analysis. Meta-analyses of cohort summary statistics were performed using GWAMA v 
2.1 79 assuming a fixed effect model. Genomic control was used to adjust the summary 
statistics for both input and output data. We prioritised for replication all variants at the p-
value ≤ 5x10-8 cutoff from the meta-analysis of 23 studies. During the course of the study, 
we updated our meta-analyses several times; variants were prioritised for replication if they 
met our cutoff (5x10-8) during any of these updates. These variants were taken forward into 
2,141 - 102,505 additional independent samples from 7 cohorts (Supplementary Table 1), 
depending on the trait. Evidence for validation was based on a Bonferroni-corrected Stage 2 
p-value of 8.6x10-4 (0.05/58) and joint meta-analysis p-value of 8.31x10-9 14.
Fine-Mapping of Associated Loci (Novel and Previously Identified Gwas Regions)
Annotation and selection of index variants for previously reported loci—For 
each trait we compiled a list of known loci by selecting all index SNPs associated with our 
traits of interest (lipids, fasting glucose, HOMA, uric acid, CRP, and blood cell counts and 
indices) from the NHGRI GWAS catalog (p-value ≤ 5x10-8, last updated in May 2014), 
supplemented by manual curation of all associations reported in the literature reaching the 
same genome-wide significance cutoff. Only those index variants with a marginal 
significance in the UK10K WGS cohort single-marker association statistics (p-value ≤ 0.05) 
were considered for conditional tests. Using TwinsUK and ALSPAC sequence data, we 
selected those variants with P-value less than 10-3 in the two-way meta-analysis. For each 
such variant we extracted regions for fine-mapping based on HapMap estimates of 
recombination rates. Where a region contained multiple correlated index variants associated 
with a given trait in the GWAS catalog, we clumped the set of index variants to remove 
highly correlated ones (using a LD metric r2>0.8 applied to within a 2 Mb sliding window 
from each known index SNP (+/-1 Mb)). This avoids collinearity errors when a variant is 
conditioned against multiple correlated index variants.
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LD Pruning of UK10K index variants—We next applied an additional LD clumping 
procedure to thin the list of variants associated with each traits, assigning sets of variants to 
discrete LD bins if their pairwise metrics r2 was ≥ 0.2. For each LD bin, the variant most 
associated with the trait in question was retained for assessment in conditional analyses. 
Index variants for previously reported loci that mapped to within +/- 1Mb of an index variant 
for a known locus were also annotated.
Conditional analyses—Sequential conditional single-variant association analyses were 
carried out to confirm statistical independence between associations. In the initial round of 
conditional analysis, associations of SNVs with the respective quantitative trait were 
conditioned on the index variants for known loci clumped (r2>0.8) as described before (this 
step was carried out only for SNVs within +/- 1Mb of a known locus); in further rounds, 
associations were conditioned against all nearby known loci plus the best novel variant 
identified in the previous round of conditional analysis. The conditional analysis was tested 
independently for each cohort, and a meta-analysis was conducted at the end of each round 
until the conditional association p-value was no longer significant (p-value>10-5). A variant 
was considered independent if it had a conditional p-value ≤ 10-5 (corresponding to r2<0.2 in 
our data).
Finally, variants were classified as ‘known’ (denoting either a previously reported GWAS 
index variant, or a variant for which the association signal disappears after conditioning on 
the known locus) or ‘novel’ (denoted as variant which still is conditionally independent on 
known loci, and on eventual other novel independent signals in that region). For novel 
signals, the variant with the lowest conditional p-value between multiple associated variants 
was reported.
Bayesian Fine Mapping methods—For each previously reported (known) association 
and each novel index variant we extracted regions for fine-mapping based on HapMap 
estimates of recombination rates according to Maller et.al. 24. Specifically, the boundaries 
were chosen to be at a distance of at least 0.1 centimorgans on either side of the index or 
known SNP and if necessary extended further to include all its tagging variants (r2>0.1 
within 1Mb windows). From the previously reported loci, only informative associations (p-
value ≤10-5 the discovery stage analysis) were taken forward. Regions with multiple SNPs 
reported to be associated to the same trait were merged if overlapping. Analysis of each 
region was then performed separately using three different methods. We implemented the 
method of Maller et al 24, by converting our discovery stage meta-analysis p-values to 
Bayes’ factors (BF) of association using Wakefield’s approximation80. Additionally, we 
employed the fine-mapping methods CAVIARBF 81 and FINEMAP 25, both Bayesian 
approaches that utilize association summary statistics (rather than the original genotypic 
data) and SNP correlations to compute BFs. The BFs from each method were then used to 
calculate posterior probabilities, based on the assumption that there is a single causal SNP in 
each region. Conditional association analysis on the top fine-mapped variant was 
additionally carried out and (conditional) fine-mapping performed in order to fine-map 
secondary associations. For all regions, 95% credible sets were constructed in order to assess 
the uncertainty of the fine-mapping analyses. To assess the suitability of our two stage fine-
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mapping approach (conditional steps) in the presence of multiple causal variants, we further 
compared our results to those obtained from FINEMAP under a relaxed assumption of 
multiple causal variants (Supplementary Note, Supplementary Table 7).
Enrichment of GWAS SNPs in Functional and Regulatory Elements—In order to 
systematically characterize the functional, cellular and regulatory contribution of genetic 
variation implicated in each quantitative trait, we used GARFIELD, a non-parametric 
enrichment analysis approach taking genome-wide association summary statistics to 
calculate fold enrichment (FE) values at given significance thresholds, and then test them for 
significance via permutation testing while accounting for linkage disequilibrium, minor 
allele frequency, and local gene density. We used a range of functional annotations, 
including genic elements (GENCODE), DNaseI hypersensitive sites, transcription factor 
binding sites, histone modifications, and chromatin states (ENCODE and Roadmap 
Epigenomics) (Supplementary Table 4) and included different cell types and tissues in order 
to capture and characterize possible cell type specific patterns of enrichment. We calculated 
FE statistics at eight genome-wide significance thresholds T (in powers of 10) and tested 
their significance at the four most stringent ones (10-8 to 10-5) to analyse both stringent 
association findings as well as nominal ones. Multiple testing correction was further 
performed on the effective number of annotations used, resulting in enrichment p-value 
threshold of 1x10-4. Further information on the approach is provided in the Supplementary 
Note.
Scoring Credible Set Variants for Regulatory Function—DeltaSVM scores were 
generated as previously published by training the gapped k-mer support vector machine 
(gkmSVM) on cell type specific DHSs, computing weights for all possible 10-mers of the 
genome based on the SVM classifier, and calculating the difference in weights of 10-mers 
encompassing the reference and effect alleles for the variant of interest 27. Pre-computed 
weights were available from a total of 222 ENCODE DHS samples—99 from the Duke 
University (Duke) set and 123 from the University of Washington (UW) set 82. Genetic 
variants were scored for deltaSVM in all 222 cell lines and filtered for those with at least one 
deltaSVM score greater than absolute 5, allowing putative inference of relevant cell types or 
tissues. CATO scores were generated as described in 28. Briefly, logistic models were fit to 
imbalance in DNA accessibility in 443 DNase-seq datasets from the ENCODE and 
Roadmap Epigenomics projects. An independent model was fit for each of 44 TF families 
and included terms for both the effect of the variant on the TF position weight matrix as well 
as terms for genomic context. Genetic variants were then scored by taking the maximum 
prediction of all overlapping TF models. CATO scores greater than 0.1 were shown to have a 
51% true positive rate on the initial training set and are therefore of interest 28.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Box 1
Biological and functional annotation of novel genetic variants and loci
Locus/Trait Description of most likely functional SNP
GFI1B/PLT Index SNP (iSNP) rs150813342 is a synonymous variant altering a predicted 
GFI1B exon 5 splice site. GFI1B is a transcription factor involved in the 
regulation of red cell and platelet production 34. Rare, heterozygous LoF 
mutations of GFI1B have been reported in hereditary thrombocytopenia 
[OMIM #187900]. rs150813342 has no LD proxies and it is predicted to be 
causative by CAVIARBF (PP=1). Furthermore, it lies within a region 
enriched for H3K4me1 and H3k36me3 in megakaryocytes 52.
NPRL3/MCH iSNP rs117747069 is a low-frequency intronic variant of NPRL3 with no LD 
proxies, predicted as the most likely causal variant (CAVIARBF PP=0.84) 
and conditionally independent of the common NPRL3 variant rs11248850 
previously associated with MCH 8. NPRL3 is known to contain nucleosome-
depleted regions involved in the regulation of the alpha-globin genes on chr 
16 8. rs117747069 is located in erythroid-specific super-enhancer 53 
54,55,52, which is hypersensitive, enriched for H3K27ac marks in 
erythroblasts, and overlapping ChIP-Seq signal for erythroid transcription 
factors GATA-1, GATA-2 and TAL-1 in K562 cells 56. While the nearest 
gene NPRL3 is a potential target of the enhancer element, chromatin 
interactions in K562 cells 56 suggest that the super-enhancer element 
interacts with several downstream genes including HBA1 and HBA2.
CCND3/MCV iSNP rs112233623 is a low-frequency intronic variant of CCND3, 
conditionally independent of the previously reported common association of 
rs9349204 with red cell traits8. Cyclin D3 plays a critical role in cell cycle 
regulation. The iSNP is located within an erythroid-specific enhancer 
37,55,52 enriched for H3K27ac mark in erythroblasts and is bound by 
GATA-2 and TAL1 in K562 cells 56. Its association with hemoglobin A2 
levels 36 also supports the role of this variant in the regulation of alpha-
globin.
HLA-DRA/WBC Index variant rs113164910 is a 2 bp indel lying in the class II MHC region, 14 
kb 3’ of HLA-DRA. The most likely fSNP rs9268781 (8 kb 3’ of HLA-DR) 
is a strong eQTL for various HLA-DR and –DQ genes in blood 57 and 
overlaps a DNaseI hypersensitive (DHS) site in blood monocytes 58. Another 
LD proxy rs7763262 has been previously associated with IgA nephropathy 
59.
HLA-B/WBC iSNP rs2442735 is located ~20 kb 5’ of the HLA-B locus and is conditionally 
independent of another HLA-B intronic SNP in the class I MHC region 
rs2853946 associated with WBC 60. The most likely fSNP rs2853999, 1 kb 
5’ of HLA-B, is a blood eQTL for HLA-C, C4A, and C4B and overlaps blood 
cell promoter and enhancer, DNase and histone marks. A proxy SNP has been 
associated with marginal zone lymphoma 61.
THPO/PLT iSNP rs78565404 is a second THPO signal, conditionally independent of the 
previously reported platelet GWAS variant rs6141 62. Both SNPs fall in the 
3’ UTR and have no LD proxies. THPO is a key regulator of platelet 
production. THPO gain-of-function mutations have been identified in 
hereditary thrombocythemia [OMIM #187950]. rs78565404 binds the 
transcription factor MAFK (ChIPSeq in HepG2 cells), a component of the 
NF-E2 complex involved in erythropoiesis and megakaryopoiesis 38,39.
GCSAML/PLT iSNP rs41315846 is located in a hematopoietic cell-lineage specific promoter 
of GCSAML (C1orf150) 58. It is conditionally independent of previously 
reported GCSAML intronic iSNP rs7550918 and has no LD proxies. 
GCSAML encodes a protein thought to be a signaling molecule associated 
with germinal centers, the sites of proliferation and differentiation of mature 
B lymphocytes. rs41315846 lies within a putative enhancer overlapping DHS 
site, RUNX1, GATA1 and FLI1 ChIP-Seq peaks and H3k27ac enriched 
region in megakaryocytes 52.
FABP6/PLT iSNP rs2546979 is a common intronic variant of FABP6, which encodes a 
fatty acid binding protein not known to play a role in platelet biology. It lies 
in a region of high LD spanning the region 5’ to the first intron of FABP6. 
The most likely fSNP (r2=0.7) rs2546372 (located ~22kb upstream of 
FABP6) overlaps regions enriched for H3k4me1 and H3k27ac signal in 
megakaryocytes, DNase, RUNX1, and FLI1 ChIP-Seq peaks 52. Another 
gene in this region, the transcription factor gene PTTG1 is highly expressed in 
bone marrow stem cells 63 and in megakaryocytes and erythroid precursors. 
Platelet promoter capture data from Blueprint shows that rs2546979 
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Locus/Trait Description of most likely functional SNP
physically interacts with neighbouring gene CCNJL, which belongs to the 
family of cyclin genes involved in cell cycle regulation. The presence of 
H3K27ac (active promoter/enhancer) in the CCNJL promoter region and 
H3K36me3 (elongation) marks in the body of this gene indicates CCNJL is 
actively expressed in megakaryocytes 52.
TRABD-MOV10L1/ PLT iSNP rs75570992 is intronic to MOV10L1, a predicted RNA helicase of 
unknown function. It is predicted to be causal (CAVIARBF PP=1) and 
associated with expression of the neighbouring gene TRABD in transformed 
fibroblasts, colon, and lymphoblastoid cells 57,33. However, another likely 
fSNP is proxy SNP rs75107793 (r2=0.5), which overlaps promoter and 
enhancer histone marks in many cell types 58, but more importantly, is 
located in a putative enhancer overlapping RUNX1 ChIP-Seq and DHS site 
and H3K4me1 enriched region in megakaryocytes 52. fSNP rs75107793 is 
also located within a DHS peak in erythroblasts, and lies upstream of TRABD 
promoter (GENCODE, FANTOM5). Based on RNA-Seq and epigenetic 
marks (H3K27ac, H3K4me3, H3H36me3), TRABD is expressed in 
megakaryocytes 52.
ZNF311/WBC iSNP rs3130725 is located in an intergenic region on chromosome 6 
containing extensive LD (>50 proxy SNPs [r2>0.8]), all of which (including 
rs3130725) are whole blood eQTLs for several genes in the region of class I 
HLA, including ZFP57, HLA-F, and HLA-H 57. The most likely fSNP is 
rs3129794, which is located in the promoter region of ZNF311 and overlaps 
an active promoter in K562 cells 58.
APOH/PLT iSNP rs1801689 encodes a Cys325Arg amino acid substitution of APOH, 
also known as beta2-glycoprotein I, a platelet phospholipid-binding protein. It 
is the most likely fSNP (PP = 0.37 by CAVIARBF), though another proxy 
SNP rs8178824 (r2=1; PP = 0.22) is located in a liver-specific promoter 
(Roadmap). Platelet promoter capture data (BLUEPRINT) shows that 
rs1801689 physically interacts with neighbouring gene PRKCA (protein 
kinase C alpha), which also plays a role in platelet function and platelet 
production in mouse models of megakaryopoiesis 64,65.
S1PR3/PLT iSNP rs61750929 is located ~100kb upstream of S1PR3, which encodes a 
receptor for sphingosine 1-phosphate (S1P) and likely contributes to the 
regulation of angiogenesis and vascular endothelial cell function.66,67. 
S1PR3 overlaps with C9orf47, a gene of unknown function. The iSNP has 33 
strong LD proxies, in an inter-genic region between MIR4289 and S1PR3/
C9orf47, several of which are cis-eQTLs for S1PR3 in whole blood 68 
positioned within megakaryocytic DHS sites (rs62549698, rs9410336) or 
H3K4Me1-enriched enhancer regions (rs9410196, rs142550358, rs9410336) 
52. Two lower LD (r2=0.5) proxies are synonymous (rs11795137) or 3’ UTR 
variants (rs62551536) of C9orf47.
RASSF3/PLT iSNP rs113373353 and all 33 of its proxies are intronic to RASSF3, a tumor 
suppressor that also promotes apoptosis. The most likely fSNP rs77164989 
(r2=0.8) lies within a putative enhancer that overlaps with DNase, H3K4me1, 
and RUNX1 ChIP-Seq peaks in megakaryocytes 52.
SHROOM3/HCT iSNP rs10008637 is intronic to SHROOM3, which encodes a protein that 
binds and regulates the subcellular distribution of F-actin 69. An intronic LD 
proxy rs13146355 of SHROOM3 is associated with lower serum creatinine 20 
and higher serum magnesium 21. Another LD proxy (r2=0.8), rs17319721, 
overlaps DHS sites in endothelial cells and is located in a TCF7L2-dependent 
enhancer increasing SHROOM3 transcription and influencing TGF-β1 
signaling and renal function70.
ABCA1/HDL The ABCA1 intronic variant rs3824477 (MAF=0.02) is in strong LD (r2 = 
0.94) with ABCA1 missense variant (rs2066718 = p.Val771Leu), previously 
nominally associated with HDL (P=10-4)23. Both SNPs are independent of 
the common ABCA1 iSNP rs1883025 for HDL 71 and the secondary ABCA1 
signal rs11789603 72. ABCA1 regulates cholesterol and phospholipid 
homeostasis. Rare loss-of-function variants of ABCA1 are associated with 
Tangier’s disease [OMIM #205400].
TP53BP1/PLT Index variant chr15:43703277 is a 1bp intronic indel of TP53BP1 located at a 
DHS site and binding site for several hematopoietic transcription factors 
including MAFK, GATA1, GATA2, and TAL1. A chromosomal aberration 
involving TP53BP1 is found in a form of myeloproliferative disorder with 
eosinophilia 73. The translocation t(5;15)(q33;q22) with PDGFRB creates a 
TP53BP1-PDGFRB fusion protein.
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Locus/Trait Description of most likely functional SNP
SLC2A9/Uric acid iSNP rs56223908 (MAF=0.08) is intronic to the urate transporter SLC2A9 
74. It has no LD proxies and it is conditionally independent of the more 
common, known SLC2A9 uric acid GWAS variant rs12498742 75. Rare 
mutations in SLC2A9 are a cause of autosomal recessive renal 
hypouricemia-2 [OMIM #612076]. The iSNP overlaps H3K4me1 enhancer 
histone marks in several Roadmap cells/tissues (blood, adrenal, muscle, heart, 
and lung) and is predicted as an active promoter in pancreas.
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Figure 1. Study design.
Summary of traits and studies investigated in this study. Study-specific information is given 
in Supplementary Table 1. HDL = high-density lipoprotein cholesterol; LDL = low-density 
lipoprotein cholesterol; TC = total cholesterol; TG = triglycerides; FG = fasting glucose; FI 
= fasting insulin; HOMA-B = homeostatic model assessment of β-cell function; HOMA-IR 
= homeostatic model assessment of insulin resistance; CRP = C-reactive protein; IL6 = 
interleukin-6; HGB = haemoglobin; RBC = red blood cell count; MCH = mean cell 
haemoglobin; MCHC = mean cell haemoglobin concentration; MCV = mean cell volume; 
PCV = packed cell volume or hematocrit; PLT = platelet count; WBC = white blood cell 
count.
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Figure 2. Allelic spectrum of cardiometabolic trait variants.
(a) For each variant surpassing the genome-wide threshold in this study, the effect size 
(measured in standard deviations) is plotted as a function of the minor allele frequency 
proportion (MAF%). Loci discovered in this study are plotted with larger symbols. 
Associations for HDL (black) and PLT (purple) for which novel variants were discovered are 
shown. The dotted line represents the curve for 80% power with a sample size of 31,749 (for 
HDL) and an alpha of 8.31x10–9. The power line for PLT (sample size 31,555) is similar and 
therefore not shown here. (b) Plot of smallest detectable effect size for a range of MAF%. 
Power calculations were performed for 4 traits of different trait groups and with different 
sample sizes: IL6, HOMA-B, LDL, and HGB.
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Figure 3. GARFIELD functional enrichment analyses.
Wheel plot displaying functional enrichment of associations with PLT within DHS hotspot 
regions in ENCODE and Roadmap studies. Radial axis shows the fold enrichment (FE) 
values calculated at each of eight GWAS P-value thresholds (T<10–1 to T<10–8) for each of 
424 cell types. Cell types are sorted by tissue, represented on the outer circle with font size 
proportional to the number of cell types from that tissue. Boxes and circles next to the tissue 
labels are coloured with respect to tissue (right legend). FE values at the different thresholds 
T areplotted with different colours on the inner side of the circle (e.g. T<10–8 in black, 
bottom-left legend).Dots in the outer side of the circle denote significant enrichment (if 
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present) for a given cell type at T<10–5 (outermost) to T<10–8 (innermost) (bottom-right 
legend). Results show overall well spread enrichment, with largest FE values obtained in 
blood, fetal spleen and fetal intestine tissues.
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Figure 4. Fine mapping experiments.
Regional association plots for loci showing fine-mapped variants. (a) Numerical summary of 
59 loci that were fine-mapped. (b) Example of fine-mapping and annotation at the LIPC 
locus for association with HDL. Panels show the regional association locuszoom plot, the PP 
statistics from the fine-mapping methods, the CATO and deltaSVM scores, VEP genic 
annotations and overlap of regulatory annotations found significant (coloured in blue) from 
GARFIELD enrichment analysis. Circles sizes and colours for all scores have been scaled 
with respect to score type (i.e. PP, CATO or deltaSVM) and numbers have been plotted 
below each circle.
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Figure 5. Fine-mapping summary of variant consequences.
(a) Number of fine-mapped trait-region pairs containing at least one variant in the 95% 
credible set with consequences (i) coding; (ii) functional score and overlapping annotation 
significantly enriched for the given trait; (iii) functional score only; (iv) significant 
enrichment overlap only; (v) none of the above. (b) Distribution of the top posterior 
probability (PP) per region for variants with significant enrichment overlap and predicted 
functional score (after removing regions containing a coding variant). Boxplots depict the 
median (thick horizontal line), 1st and 3rd quartiles (coloured box), maximum and minimum 
values (whiskers) and outlying values (circles). (c) Proportions of variants within credible 
sets with coding, regulatory or no annotations.
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